BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 8534270)

  • 1. Radiolabelling of the human 5-HT2A receptor with an agonist, a partial agonist and an antagonist: effects on apparent agonist affinities.
    Sleight AJ; Stam NJ; Mutel V; Vanderheyden PM
    Biochem Pharmacol; 1996 Jan; 51(1):71-6. PubMed ID: 8534270
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 3H-DOB (4-bromo-2,5-dimethoxyphenylisopropylamine) labels a guanyl nucleotide-sensitive state of cortical 5-HT2 receptors.
    Lyon RA; Davis KH; Titeler M
    Mol Pharmacol; 1987 Feb; 31(2):194-9. PubMed ID: 3543649
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Selectivity of serotonergic drugs for multiple brain serotonin receptors. Role of [3H]-4-bromo-2,5-dimethoxyphenylisopropylamine ([3H]DOB), a 5-HT2 agonist radioligand.
    Titeler M; Lyon RA; Davis KH; Glennon RA
    Biochem Pharmacol; 1987 Oct; 36(19):3265-71. PubMed ID: 3663239
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [3H]-DOB(4-bromo-2,5-dimethoxyphenylisopropylamine) and [3H] ketanserin label two affinity states of the cloned human 5-hydroxytryptamine2 receptor.
    Branchek T; Adham N; Macchi M; Kao HT; Hartig PR
    Mol Pharmacol; 1990 Nov; 38(5):604-9. PubMed ID: 2233697
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 4-[125I]iodo-(2,5-dimethoxy)phenylisopropylamine and [3H]ketanserin labeling of 5-hydroxytryptamine2 (5HT2) receptors in mammalian cells transfected with a rat 5HT2 cDNA: evidence for multiple states and not multiple 5HT2 receptor subtypes.
    Teitler M; Leonhardt S; Weisberg EL; Hoffman BJ
    Mol Pharmacol; 1990 Nov; 38(5):594-8. PubMed ID: 2233696
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multiple conformations of native and recombinant human 5-hydroxytryptamine(2a) receptors are labeled by agonists and discriminated by antagonists.
    López-Giménez JF; Villazón M; Brea J; Loza MI; Palacios JM; Mengod G; Vilaró MT
    Mol Pharmacol; 2001 Oct; 60(4):690-9. PubMed ID: 11562430
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differentiation of 5-hydroxytryptamine2 receptor subtypes using 125I-R-(-)2,5-dimethoxy-4-iodo-phenylisopropylamine and 3H-ketanserin.
    McKenna DJ; Peroutka SJ
    J Neurosci; 1989 Oct; 9(10):3482-90. PubMed ID: 2795135
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Site-directed mutagenesis of the serotonin 5-hydroxytrypamine2 receptor: identification of amino acids necessary for ligand binding and receptor activation.
    Wang CD; Gallaher TK; Shih JC
    Mol Pharmacol; 1993 Jun; 43(6):931-40. PubMed ID: 8316224
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of homogeneous high-affinity agonist binding assays for 5-HT2 receptor subtypes.
    Song J; Hanniford D; Doucette C; Graham E; Poole MF; Ting A; Sherf B; Harrington J; Brunden K; Stricker-Krongrad A
    Assay Drug Dev Technol; 2005 Dec; 3(6):649-59. PubMed ID: 16438660
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacological characterisation of the agonist radioligand binding site of 5-HT(2A), 5-HT(2B) and 5-HT(2C) receptors.
    Knight AR; Misra A; Quirk K; Benwell K; Revell D; Kennett G; Bickerdike M
    Naunyn Schmiedebergs Arch Pharmacol; 2004 Aug; 370(2):114-23. PubMed ID: 15322733
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High affinity agonist binding to cloned 5-hydroxytryptamine2 receptors is not sensitive to GTP analogs.
    Szele FG; Pritchett DB
    Mol Pharmacol; 1993 Jun; 43(6):915-20. PubMed ID: 8316223
    [TBL] [Abstract][Full Text] [Related]  

  • 12. (R)-(-)-[77Br]4-bromo-2,5-dimethoxyamphetamine labels a novel 5-hydroxytryptamine binding site in brain membranes.
    Peroutka SJ; Hamik A; Harrington MA; Hoffman AJ; Mathis CA; Pierce PA; Wang SS
    Mol Pharmacol; 1988 Oct; 34(4):537-42. PubMed ID: 3173334
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Involvement of 5-HT(1B/1D) and 5-HT2A receptors in 5-HT-induced contraction of endothelium-denuded rabbit epicardial coronary arteries.
    Ellwood AJ; Curtis MJ
    Br J Pharmacol; 1997 Nov; 122(5):875-84. PubMed ID: 9384503
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evidence for distinct 5-hydroxytryptamine2 binding site subtypes in cortical membrane preparations.
    Pierce PA; Peroutka SJ
    J Neurochem; 1989 Feb; 52(2):656-8. PubMed ID: 2911036
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Autoradiographic characterization of (+-)-1-(2,5-dimethoxy-4-[125I] iodophenyl)-2-aminopropane ([125I]DOI) binding to 5-HT2 and 5-HT1c receptors in rat brain.
    Appel NM; Mitchell WM; Garlick RK; Glennon RA; Teitler M; De Souza EB
    J Pharmacol Exp Ther; 1990 Nov; 255(2):843-57. PubMed ID: 2243353
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative recovery kinetics of 5-hydroxytryptamine 1A, 1B, and 2A receptor subtypes in rat cortex after receptor inactivation: evidence for differences in receptor production and degradation.
    Pinto W; Battaglia G
    Mol Pharmacol; 1994 Dec; 46(6):1111-9. PubMed ID: 7808431
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Selective visualization of rat brain 5-HT2A receptors by autoradiography with [3H]MDL 100,907.
    López-Giménez JF; Mengod G; Palacios JM; Vilaró MT
    Naunyn Schmiedebergs Arch Pharmacol; 1997 Oct; 356(4):446-54. PubMed ID: 9349630
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [3H]Rauwolscine: an antagonist radioligand for the cloned human 5-hydroxytryptamine2b (5-HT2B) receptor.
    Wainscott DB; Sasso DA; Kursar JD; Baez M; Lucaites VL; Nelson DL
    Naunyn Schmiedebergs Arch Pharmacol; 1998 Jan; 357(1):17-24. PubMed ID: 9459568
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Regulation of 5-HT2 receptors in rat cortex. Studies with a putative selective agonist and an antagonist.
    Pranzatelli MR
    Biochem Pharmacol; 1991 Aug; 42(5):1099-105. PubMed ID: 1872895
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High-affinity agonist binding correlates with efficacy (intrinsic activity) at the human serotonin 5-HT2A and 5-HT2C receptors: evidence favoring the ternary complex and two-state models of agonist action.
    Fitzgerald LW; Conklin DS; Krause CM; Marshall AP; Patterson JP; Tran DP; Iyer G; Kostich WA; Largent BL; Hartig PR
    J Neurochem; 1999 May; 72(5):2127-34. PubMed ID: 10217294
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.